Table 3:

Active clinical trials exploring palbociclib use with checkpoint inhibitors.

Name/Identifier	Phase	Setting	Interventions	Primary Outcome Measures
NCT03573648 ImmunoADAPT	II	NA	Palbociclib, tamoxifen and avelumab Tamoxifen and avelumab only	Rate of cCR at 2 years Safety and tolerability
NCT04075604 CheckMate7A8	II	NA	Palbociclib, anastrozole and nivolumab Palbociclib and anastrozole then palbociclib, anastrozole, and nivolumab Palbociclib and anastrozole	Residual cancer burden rate Dose limiting toxicity
NCT02778685	II	M	Letrozole, palbociclib and pembrolizumab	Response rate and duration of response
NCT03147287 PACE	II	M	Fulvestrant Palbociclib and fulvestrant Palbociclib, fulvestrant and avelumab	PFS at 2 years Overall response rate Safety and tolerability

Abbreviations: (cCR) Clinical complete response; (M) Metastatic; (NA) Neoadjuvant; (PFS) Progression-free survival